USPTO serial 79296890
EXOTHERA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 24, 2021
- Examiner
- STRUCK, ROBERT J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with EXOTHERA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 040 | Custom manufacturing of biologics, namely, manufacturing of biologics using biological organisms in the manufacturing process; custom manufacturing of pharmaceuticals, antibiotic medicines and materials for clinical trials and for commercial supply by pharmaceutical compounders; bio manufacturing for others, namely, custom manufacturing of pharmaceuticals and materials for clinical trials for commercial supply, using biological organisms in the manufacturing process; custom manufacturing services in the field of biologics, pharmaceuticals, biopharmaceuticals, health care, cell culture and gene therapy and medical products; custom manufacturing of medications and parts of medications on the base of specific compositions or active constituents for others to support clinical trials and commercial supply; treatment of pharmaceutical and chemical products and their components during the custom manufacture of pharmaceuticals and biopharmaceuticals; providing advice related to the custom manufacture of pharmaceuticals and materials for clinical trials and for commercial supply; providing information in the field of the custom manufacture of pharmaceuticals and materials for clinical trials and for commercial supply | ACTIVE | — |
| 042 | Scientific research and development applied in particular in the biological, technological and biotechnological fields, in the medical, biomedical, chemical, pharmaceutical and veterinary fields, in the fields of immunology, epidemiology, vaccinology and therapies and in the field of gene and cellular therapy; scientific and technological research and development for the pharmaceutical and biotechnology industries; quality control services on pharmaceutical products for others; scientific research and technological development and advice services, namely, analytical testing, biosafety testing, reporting and laboratory services for others, custom design and development of chemical reagents and biochemical assays, formulation and process development for the manufacturing of medicinal products; engineering services; scientific and technological consultancy on process development relating to manufacture of biologics; industrial process development for manufacturing of medical preparations; engineering services and scientific and technological consultancy, all on production units for the development of biologics; design of tools for the production of biologics; advisory services relating to industrial engineering in the field of manufacturing of biologics; biochemical engineering services; technical engineering services in the field of manufacturing of biologics; rental of laboratory apparatus and instruments; technological development services, technology advice and information services and engineering consultation services in the field of the production of biologics; scientific research services in the medical sector, namely, conducting clinical trials for others; providing scientific research information in the medical sector, in the field of clinical trials; scientific laboratory services related to the culture of stem cells or differentiated cells and biological materials to be used in cellular therapies and in clinical trials and for the manufacturing of commercial products | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by EXOTHERA, société anonyme
- Other trademarks owned by EXOTHERA, société anonyme
- Other trademarks owned by EXOTHERA, société anonyme
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named EXOTHERA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 24, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 3, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 28, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 4, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 3, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 24, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 24, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 29, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 29, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 29, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 8, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 8, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 19, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 9, 2021 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| May 6, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 29, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 28, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 28, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 22, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 26, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 26, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 6, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 5, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 3, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 6, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 2, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 29, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |